Firefly Neuroscience (AIFF) Non-Current Deffered Revenue (2025 - 2026)
Firefly Neuroscience (AIFF) posted Non-Current Deffered Revenue of $7000.0 for Q2 2026, down 50.0% on a QoQ basis from $14000.0 in Q1 2026, and down 83.72% year-over-year from $43000.0 in Q2 2025.
Powered by 
Analysis
Firefly Neuroscience (AIFF) Non-Current Deffered Revenue (2025 - 2026) Analysis & Trends
Firefly Neuroscience has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $7000.0 in Q2 2026.
- On a quarterly basis, Non-Current Deffered Revenue fell 83.72% year-over-year to $7000.0 in Q2 2026; TTM through Jun 2026 was $7000.0, a 83.72% decrease from a year earlier, with the FY2025 full-year figure at $21000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was $7000.0 for Q2 2026 at Firefly Neuroscience, down from $14000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $43000.0 in Q2 2025, with the low at $7000.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 31.10 Bn | 29.22 Bn | 2.18 Bn | - |
| 2 | Lantheus Holdings | 6.59 Bn | 6.00 Bn | 241.86 Mn | - |
| 3 | Heartflow | 4.24 Bn | 3.87 Bn | 53.19 Mn | - |
| 4 | Neogen | 2.58 Bn | 2.39 Bn | 107.80 Mn | - |
| 5 | Butterfly Network | 1.75 Bn | 1.62 Bn | 23.29 Mn | 10.19 Mn |
| 6 | QuidelOrtho | 954.15 Mn | 830.75 Mn | - | - |
| 7 | Ceribell | 944.88 Mn | 815.62 Mn | 25.94 Mn | - |
| 8 | Anbio Biotechnology | 941.05 Mn | 929.15 Mn | - | - |
| 9 | Varex Imaging | 780.16 Mn | 694.86 Mn | 76.70 Mn | - |
| 10 | Firefly Neuroscience | 23.25 Mn | 14.03 Mn | 253,000.00 | 7,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7,000.00 |
| Mar 31, 2026 | 14,000.00 |
| Dec 31, 2025 | 21,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 43,000.00 |